SCHEMBL30026290

SCHEMBL30026290

COc1ccccc1-c1c(F)cc2[nH]cnc2c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.46
▸ MAP2 P11137 1/20 0.41
▸ IDO1 P14902 2/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ MAP4K1 Q92918 2/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ RAD52 P43351 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ ALOX5AP P20292 2/20 0.37
▸ FEN1 P39748 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30026631 0.83 MAPT (0.41) BRD4IDO1HTR3AMEN1ALDH1A1
SCHEMBL28518771 0.78 MAP2 (0.40) MAP2MAP4K1ALOX5APFEN1KDM4E
SCHEMBL16109429 0.70 APP (0.50) MAP2KDM4EMEN1ALDH1A1MAPT
SCHEMBL2092087 0.70 APP (0.50) MAP2KDM4EMEN1ALDH1A1MAPT
SCHEMBL24589022 0.70 MAP2 (0.46) MAP2HTR3AKDM4EMEN1ALDH1A1
SCHEMBL6956986 0.68 MAPT (0.46) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL10227251 0.68 APP (0.55) MAP2KDM4EMEN1ALDH1A1MAPT
SCHEMBL17812973 0.67 APP (0.47) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL24589302 0.67 APP (0.47) MAP2HTR3AMEN1ALDH1A1HPGD
SCHEMBL24589023 0.67 MAP2 (0.46) MAP2HTR3AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2025-01-07 — — US disclosed
US-20230130361-A1 Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2023-04-27 — — US disclosed
US-11512055-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2022-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512055-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof RORC, RORB, RORA BRD4 548/4885MAP2 3360/4885IDO1 3392/4885
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof RORC, RORB, RORA BRD4 579/4885MAP2 3287/4885IDO1 3346/4885
US-20230130361-A1 Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof RORB, RORA, RORC BRD4 772/4885MAP2 2625/4885IDO1 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback